Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients
Antiviral Therapy · 2017-08 · 22 (6) · 481-493
DOI: 10.3851/imp3117 ↗At a glance
Journal article in Antiviral Therapy, published online on 2016-08-01. Written by Lisa I Backus and 4 co-authors. Institution: Department of Veterans Affairs, Population Health Services, Palo Alto Health Care System, Palo Alto, CA, USA. Major MEDLINE topics: Genotype. Cited 67 times so far (Crossref); 24 references.
Abstract (original language)
Background
Predictors of sustained virological response (SVR) to all-oral HCV regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ±RBV) and ombitasvir/paritaprevir/ ritonavir + dasabuvir (OPrD) ±RBV in patients treated in routine practice.
Methods
Observational, intent-to-treat cohort of 21,142 genotype-1 patients initiating 8 or 12 weeks of LDV/SOF ±RBV or 12 weeks of OPrD ±RBV at any Veterans Affairs facility. Multivariate logistic regression models were constructed to model SVR and identify predictors.
Results
SVR was 91.2% (9,781/10,720) for LDV/ SOF, 89.6% (3,266/3,646) for LDV/SOF+RBV, 91.7% (1,197/1,306) for OPrD and 87.8% (3,365/3,832) for OPrD+RBV. For LDV/SOF ±RBV, reduced odds of SVR occurred in African-Americans (0.80, 95% CI 0.70, 0.92, P
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Veterans Affairs, Population Health Services, Palo Alto Health Care System, Palo Alto, CA, USA.
Cite
APA
Backus, L. I., Belperio, P. S., Shahoumian, T. A., Loomis, T. P., & Mole, L. A. (2017). Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients. Antiviral Therapy, 22(6), 481-493. https://doi.org/10.3851/imp3117
Vancouver
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients. Antiviral Therapy. 2017;22(6):481-493. doi:10.3851/imp3117
BibTeX
@article{Backus2017,
author = {Backus, Lisa I and Belperio, Pamela S and Shahoumian, Troy A and Loomis, Timothy P and Mole, Larry A},
title = {Real-World Effectiveness and Predictors of Sustained Virological Response with All-Oral Therapy in 21,242 Hepatitis C Genotype-1 Patients},
journal = {Antiviral Therapy},
year = {2017},
volume = {22},
number = {6},
pages = {481--493},
doi = {10.3851/imp3117}
}
EUVIMED